Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
NCT ID: NCT00419393
Last Updated: 2014-09-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
190 participants
INTERVENTIONAL
2007-12-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
NCT00150709
An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
NCT01506882
Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures
NCT00152516
A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures
NCT00367432
Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy
NCT01498822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Keppra XR (Levetiracetam XR)
1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
Keppra XR (Levetiracetam XR)
500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Keppra XR (Levetiracetam XR)
500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
12 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center, MD
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dothan, Alabama, United States
Northport, Alabama, United States
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Bakersfield, California, United States
Loxahatchee Groves, Florida, United States
Atlanta, Georgia, United States
Suwanee, Georgia, United States
Witchita, Kansas, United States
Detroit, Michigan, United States
Camden, New Jersey, United States
Buffalo, New York, United States
Cedarhurst, New York, United States
Toledo, Ohio, United States
Tulsa, Oklahoma, United States
San Antonio, Texas, United States
Aguascalientes, , Mexico
Guadalajara, , Mexico
Guadalajara Jalisco, , Mexico
Mexico City, , Mexico
Monterrey, , Mexico
Bialystok, , Poland
Gdansk, , Poland
Katowice, , Poland
Lodz, , Poland
Lublin, , Poland
Poznan, , Poland
Szczecin, , Poland
Warsaw, , Poland
Kalingrad, , Russia
Kazan', , Russia
Moscow, , Russia
Saint Petersburg, , Russia
Samara, , Russia
Yaroslavl, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-000899-17
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
N01281
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.